Scotiabank raised the firm’s price target on Twist Bioscience to $48 from $43 and keeps an Outperform rating on the shares. The company’s Q2 results beat consensus and guidance across the board, the analyst tells investors. Looking forward, the company has significant headroom growth for both SynBio and NGS, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $55 from $48 at TD Cowen
- Twist Bioscience price target raised to $40 from $39 at Baird
- Twist Bioscience price target raised to $45 from $40 at Barclays
- Twist Bioscience raises FY24 revenue view to $300M-$304M from $288M-$293M
- Twist Bioscience sees Q3 revenue $77M, consensus $73.8M